Thus, UCHL3 inhibition may offer a worthy therapeutic opportunity for cancer cells that possess upregulated PDB repair mechanisms, particularly those that exploit this upregulation as a mechanism to resist TOP1 targeting chemotherapy. Here, TOP1 is linked to cancer.